Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289333466> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4289333466 endingPage "JC92" @default.
- W4289333466 startingPage "JC92" @default.
- W4289333466 abstract "ACP Journal ClubAugust 2022In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19Gabriel M. Aisenberg, MDGabriel M. Aisenberg, MDUniversity of Texas, Houston, Houston, Texas, USA (G.M.A.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0056 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLevin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188-200. https://pubmed.ncbi.nlm.nih.gov/35443106Clinical Impact RatingsInfectious Disease: References1. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305-15. [PMID: 34937145] Google Scholar2. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-20. [PMID: 34914868] Google Scholar3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385:e81. [PMID: 34587383] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas, Houston, Houston, Texas, USA (G.M.A.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0056.This article was published at Annals.org on 2 August 2022.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics August 2022Volume 175, Issue 8Page: JC92KeywordsCOVID-19DisclosureMonoclonal antibodiesNumber needed to treatOmicron variantProphylaxisProteinsReinfectionSafetyVaccines ePublished: 2 August 2022 Issue Published: August 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ..." @default.
- W4289333466 created "2022-08-02" @default.
- W4289333466 creator A5001173790 @default.
- W4289333466 date "2022-08-01" @default.
- W4289333466 modified "2023-09-30" @default.
- W4289333466 title "In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19" @default.
- W4289333466 doi "https://doi.org/10.7326/j22-0056" @default.
- W4289333466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35914259" @default.
- W4289333466 hasPublicationYear "2022" @default.
- W4289333466 type Work @default.
- W4289333466 citedByCount "1" @default.
- W4289333466 countsByYear W42893334662023 @default.
- W4289333466 crossrefType "journal-article" @default.
- W4289333466 hasAuthorship W4289333466A5001173790 @default.
- W4289333466 hasConcept C126322002 @default.
- W4289333466 hasConcept C142724271 @default.
- W4289333466 hasConcept C159047783 @default.
- W4289333466 hasConcept C195244886 @default.
- W4289333466 hasConcept C22070199 @default.
- W4289333466 hasConcept C2777445551 @default.
- W4289333466 hasConcept C2779134260 @default.
- W4289333466 hasConcept C2780708616 @default.
- W4289333466 hasConcept C3008058167 @default.
- W4289333466 hasConcept C512399662 @default.
- W4289333466 hasConcept C524204448 @default.
- W4289333466 hasConcept C71924100 @default.
- W4289333466 hasConcept C95457728 @default.
- W4289333466 hasConceptScore W4289333466C126322002 @default.
- W4289333466 hasConceptScore W4289333466C142724271 @default.
- W4289333466 hasConceptScore W4289333466C159047783 @default.
- W4289333466 hasConceptScore W4289333466C195244886 @default.
- W4289333466 hasConceptScore W4289333466C22070199 @default.
- W4289333466 hasConceptScore W4289333466C2777445551 @default.
- W4289333466 hasConceptScore W4289333466C2779134260 @default.
- W4289333466 hasConceptScore W4289333466C2780708616 @default.
- W4289333466 hasConceptScore W4289333466C3008058167 @default.
- W4289333466 hasConceptScore W4289333466C512399662 @default.
- W4289333466 hasConceptScore W4289333466C524204448 @default.
- W4289333466 hasConceptScore W4289333466C71924100 @default.
- W4289333466 hasConceptScore W4289333466C95457728 @default.
- W4289333466 hasIssue "8" @default.
- W4289333466 hasLocation W42893334661 @default.
- W4289333466 hasLocation W42893334662 @default.
- W4289333466 hasOpenAccess W4289333466 @default.
- W4289333466 hasPrimaryLocation W42893334661 @default.
- W4289333466 hasRelatedWork W2113259527 @default.
- W4289333466 hasRelatedWork W2140758886 @default.
- W4289333466 hasRelatedWork W2168106826 @default.
- W4289333466 hasRelatedWork W2336862218 @default.
- W4289333466 hasRelatedWork W2417582085 @default.
- W4289333466 hasRelatedWork W4210751118 @default.
- W4289333466 hasRelatedWork W4243398527 @default.
- W4289333466 hasRelatedWork W4248785221 @default.
- W4289333466 hasRelatedWork W4287733513 @default.
- W4289333466 hasRelatedWork W4313651810 @default.
- W4289333466 hasVolume "175" @default.
- W4289333466 isParatext "false" @default.
- W4289333466 isRetracted "false" @default.
- W4289333466 workType "article" @default.